Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
Unknown status
Medical College of Wisconsin
Phase 1
1994-05-01
RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and
may be an effective treatment for refractory brain tumors.
PURPOSE: This phase I trial is studying the side effects and best dose of photodynamic
therapy using porfimer sodium in treating patients with refractory brain tumors, including
astrocytoma, ependymoma, and medulloblastoma.
Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
Completed
Roswell Park Cancer Institute
Phase 2
1995-10-01
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to
light to kill tumor cells. This may be an effective treatment for esophageal cancer.
PURPOSE: Phase II trial to study the effectiveness of photodynamic therapy in treating
patients with Barrett's esophagus who have in situ esophageal cancer.
Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer
Completed
Roswell Park Cancer Institute
Phase 2
1995-02-01
RATIONALE: Drugs that make cancer cells more visible to light may help in the diagnosis of
head and neck cancer.
PURPOSE: Phase II trial to study the usefulness of porfimer sodium in diagnosing patients
with head and neck cancer.
Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
Unknown status
Colorado Health Foundation
Phase 3
1998-04-01
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to
light to kill tumor cells. It is not yet known if the addition of photodynamic therapy to
combined therapy with surgery, radiation therapy, and chemotherapy is more effective than
combined therapy alone for supratentorial gliomas.
PURPOSE: Randomized phase III trial to study the effectiveness of surgery, radiation therapy,
and chemotherapy with or without photodynamic therapy in treating patients who have newly
diagnosed or recurrent malignant supratentorial gliomas.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
